.Nature Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a mean follow-up of 11 months, individuals with metastatic stomach growths who got biomarker-matched treatments based upon circulating cyst DNA profiling showed a more significant scientific advantage than those acquiring unequaled treatment.